| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697031 | Brachytherapy | 2017 | 8 Pages |
Abstract
Interstitial BT used as part of the primary or postoperative treatment of vulvar carcinoma is feasible with a satisfactory toxicity profile. Prognosis remains, however, dismal, with a high frequency of failures in patients with locally advanced tumors.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
P. Castelnau-Marchand, A. Escande, R. Mazeron, E. Bentivegna, A. Cavalcanti, S. Gouy, C. Baratiny, P. Maroun, P. Morice, C. Haie-Meder, C. Chargari,